Arterion will present at the Medtech Investment Day Nordic in Stockhom September 13.
Take the oportunity to meet wit CEO Karl Richard Nilsson to discuss the uppcoming investmetn oportunity.
Arterion welcomes Dr. Gisela Sitbon to the board.
Gisela holds a PhD in Molecular Biology from Karolinska Institutet and has more than 20 years of experience from working with business development in small and medium sized companies within life science. Apart from Arterion Gisela is involved in several other companies eg. Industrifonden and Nanologica AB.
Gisela has also worked as eg. group leader at Karo Bio AB and as CEO at Professional Genetics Laboratory AB.
Gisela brings a lot of enthusiasm together with a lot of experience from the life science industry.
At the ICI Meeting in Tel Aviv, Israel, December 4-6 Arterion will pressent their business case at the ICI Innovation Award.
Take the oportunity to meet with CEO Karl Richard Nilsson and to see and feel the cellulose grafts Arterion are developing.
Arterion is one of the presenting companies at Göteborgs Kapitalmarknadsdag on September 15. Arterion will present at 16:30 but will be represented during the entire event.
Om March 10 Arteiron’s shareholders appointed Johan Westman as the new chairman of the board. Johan began his career in the pharmaceutical and biotech industry in 1987, working for Steridose in Gothenburg Sweden in project management and sales of aseptically designed systems. In 1995, he moved to NovAseptic AB, Sweden, starting as Sales Manager, then spending three years as manager for the US American subsidiary and finally holding the position of Manager and CEO of the entire company in 2001. Since Millipore acquired NovAseptic in 2005, Johan took the position of VP Marketing of Millipore’s Advanced Manufacturing Solutions.
In January Arterion got it's first granted patent in South Africa. ZA Patent No. 2009/02973.
Arteiron will present at the In3 Europe conference in Paris, March 15, 2011.
More information about In3 Europe can be found at the conference webpage.
Arterion will present at the 12th MedTech Investing Europe Conference, March 7-8 2011 in Lausanne.
More info about the conference can be found at the conference webpage.
Arterion was awarded €35 000 from GöteborgBIO for the development of artificial vascular grafts. This development will be performed together with associate professor Carl Johan Franzén, Industrial Biotechnology at Chalmers
More info at GöteborgBIO's and Chalmers webpages.
Arterion is glad to announce the growth of the company as we welcome Mehrdad to the team. Mehrdad holds a PhD in microbiology and has held several QA-positions in the med-tech area. QA as well as process development will be two of Mehrdads main focus areas.
On March 1 at 20:00 (CET) and on March 6 at 13:50 there will be a story about Arterion's academic partners and their progress in developing artificial vascular grafts made from bacterial cellulose. The show is Vetenskapens Värld (in Swedish).
Arterion will present at the Translational Regenerative Medicine Foundation Venture Forum in Winston-Salem, NC, April 8, 2010.
As a selected presenter Arterion will talk about business opportunities for investors as well as collaboration opportunities for research partners and commercial partners.
Arterion have been rewarded the Medtech Investment Day Award 2010 having the the highest potential to become an international expanding medtech company.
Swedish Medtech had together with sponsors invited 22 companies who had the chance to pitch their companies towards an international group of investors. Arterion was the sole winner and the jury motivated their choice by explaining that Arterion has an elegant and innovative idea for a medical necessity and that Arterions's technology can be applied to many applications but today is focused on one. The jury also describe Arterion as an "enthusiastic and humble team with high competence".
As a prize, Arterion was awarded a one year membership with Swecare and SEK 50 000. Further information and comments by Arterion CEO Karl Richard Nilsson, see the links below.
Arterion welcomes the new Production Manager Kristoffer Drotz. Kristoffer's already has a deep insight and knowledge in bacterial cellulose and his earlier work includes e.g. Laboratory Manager att Arterion's academic research partner BBV.
Arterion were invited to speak at the 'From Discovery to Market'-workshop hosted by North Carolina Department of Commerce and Region Västra götaland, Sweden together with Virginia Tech, Wake Forest University and Piedmont Triad Research Park. The workshop took place on WFIRM, Winston-Salem, NC USA, November 4-5, 2008.
Arterion was awarded second prize in the national innovation competion SKAPA.
Arterion moves to Biotech Center at Arvid Wallgrens Backe 20.
Arterion was mentioned as one of Sweden's 33 most interesting startups in the papers Affärsvärlden and Ny Teknik.
Arterion was awarded 300 000 SEK from the Swedish Govermental Agency for Innovation Systems, Vinnova.
The prize is awarded as part of the VinnNu programme to fule the most promising innovations of Sweden.
An article about Arterion was published in GöteborgsPosten.
The research team behind Arterion's technology has been awarded 10 million SEK in govermental funding for research in the field of artificial vessels made of cellulose.
The innovators behind the Arterion technology has been the focus of an article published in NyTeknik nr 3.
Arterion moves to new facilities at Sahlgrenska Science Park.
Arterion has been choosen as the "Best business potential 2006 at Chalmers School of Entrepreneurship and GIBBS"
Full paged story about Arterion in Biotech Sweden nr 11.
Arterion was given 3rd prize in Venture Cup 2006. Venture Cup is a business plan competition with the objective to stimulate entrepreneurship and to increase the founding of new companies in Sweden. Anyone with an innovative concept who wants to start a business is welcome to participate in Venture Cup.